A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

NIAID Data Ecosystem2026-03-13 收录

I期临床试验

KRAS靶向治疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2743980 数据链接链接失效反馈

官方服务：

资源简介：

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.

创建时间：

2022-08-15

Supplementary Table S4 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy

合成致死筛选

KRAS靶向治疗

Supplementary Table S4 MaGeCK analysis of MRTX-849/TNO155 CRISPR/Cas9 screens of NSCLC cell lines

Figshare2023-12-15 更新60

Dataset from A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants

药代动力学

I期临床试验

This is double-blind, randomized, sequential, two part study. Part 1 is a 3 periods, fixed-sequence study and will be conducted to evaluate the pharmacokinetics, safety, and tolerability of the gepo

NIAID Data Ecosystem30

Single-center, double-blind, randomized, placebo-controlled, single andmultiple dose escalation study to assess safety and tolerability and pharmacokinetics of HRX215 in healthy male volunteers under food and fasting conditions

I期临床试验

肝再生药物开发

Diminished hepatocyte regeneration is a key feature of acute and chronic liver diseases and after extended liver resections, resulting in the inability to maintain or restore a sufficient functional l

Zenodo2024-03-15 更新00

Dataset from A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban

I期临床试验

药代动力学与安全性评估

The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat

NIAID Data Ecosystem30

Available IPD datapackage for study 'Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants'

I期临床试验

坐骨神经痛药物评估

The primary objective of the study is to determine the safety/tolerability profile, systemic PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica participants.

DataCite Commons2025-07-07 更新00

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

资源简介：

相关数据集